

CLOROX CO /DE/
Form 8-K
March 12, 2018

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 12, 2018

THE CLOROX COMPANY
(Exact name of registrant as specified in its charter)

Delaware

1-07151

31-0595760

(State or other jurisdiction of incorporation) (Commission File Number)

(I.R.S. Employer

Identification No.)

1221 Broadway, Oakland, California 94612-1888
(Address of principal executive offices) (Zip code)

(510) 271-7000
(Registrant's telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 Under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).

Emerging growth company “

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. “

Item 8.01 Other Events

On March 12, 2018, The Clorox Company issued a press release announcing the entry of its subsidiary ReNew Life Holdings Corporation into a unit purchase agreement with Nutranext Holdings, LLC and NeoCell Holding Company, LLC to acquire all of the outstanding interests of Nutranext, LLC and New NeoCell, LLC. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) See Exhibit Index below.

EXHIBIT INDEX

Exhibit No.	Description
<u>99.1</u>	<u>Press Release of The Clorox Company, dated March 12, 2018.</u>

Edgar Filing: CLOROX CO /DE/ - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

THE CLOROX COMPANY

Date: March 12, 2018 By: /s/ Laura Stein
Executive Vice President
General Counsel and Corporate Affairs
